60° Pharmaceuticals (60P) receives priority review designation for Malaria Drug
60 Degrees Pharmaceuticals (60P) received Priority Review Designation from the United States Food and Drug Administration (USFDA) for Tafenoquine (TQ) for prevention of malaria in adults.
The FDA informed 60P of this designation upon filing of its’ New Drug Application (NDA).
USFDA priority review is granted when a drug is intended to treat a serious condition and would “provide a significant improvement in safety or effectiveness”1 over currently available options. The USFDA goal for completing a priority review of an NDA is six months. This designation is often used in combination with other expedited review processes.
In January 2018, 60P received USFDA Fast Track Designation for the use of Tafenoquine to prevent malaria in adults traveling to areas where the disease is prevalent.
Malaria, a life-threatening disease transmitted through the bite of an infected mosquito, poses a significant risk to millions of healthy individuals traveling in many parts of the world, including employees of non-governmental organizations, casual vacationers, industrial and business workers, and military forces.2 Malaria cases among travelers returning to the U.S. are trending upwards, with 84% of those infected requiring hospitalization.3 In 2015, there were 212 million clinical cases and malaria caused an estimated 429,000 fatalities.4
“We see Priority Review, following our Fast Track Designation, as a validation of the importance of this therapy. TQ will provide a significant improvement over currently available therapies. TQ has the advantage of a convenient weekly dosing regimen which will help travelers comply and protect themselves from malaria parasite(s) while in endemic regions of the world” said Geoffrey Dow, Ph.D., CEO, 60 Degrees Pharmaceuticals.
Dr. Dow further commented that “receiving priority review expedites the review of Tafenoquine and indicates that the product potentially fulfils the statutory requirements for a priority review voucher (PRV). Receiving a PRV would assist 60P in acquiring needed resources to launch Tafenoquine.”
In 2014, 60P entered into a cooperative research and development agreement with the U.S. Army Medical Materiel Development Activity to develop Tafenoquine, which was discovered at the Walter Reed Army Institute of Research. Since malaria is the top infectious disease threat to U.S. Military service members overseas, the military maintains a robust anti-malarial drug development effort through internal research and commercial partnerships.
An analysis of five clinical trials to assess the safety and tolerability of Tafenoquine has recently been published in Travel Medicine and Infectious Disease, a peer reviewed journal. The authors concluded that Tafenoquine appeared to be safe and well tolerated when the anticipated clinical regimen (ACR) was administered.